Phase 1 participant characteristics
| Variable | Number of participants (%) | |
| Sex | Male | 19 (54.3) |
| Female | 16 (45.7) | |
| Age | ≤54 | 12 (34.3) |
| 55–64 | 6 (17.1) | |
| 65–74 | 12 (34.3) | |
| ≥75 | 5 (16.3) | |
| Procedure | OGD (including transnasal endoscopy) | 15 (42.8) |
| Colonoscopy | 10 (28.6) | |
| CTC | 10 (28.6) | |
| Indication | Alarm symptoms | 12 (34.3) |
| Routine symptoms | 17 (48.6) | |
| Surveillance procedures | 6 (17.1) | |
CTC, CT colonography; OGD, oesophagogastroduodenoscopy.